These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16052239)

  • 1. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prescription Drug User Fee Act: Much More Than User Fees.
    Mitchell AP; Trivedi NU; Bach PB
    Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Market watch: Upcoming catalysts in Q1 2015.
    Uribe A
    Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
    [No Abstract]   [Full Text] [Related]  

  • 8. Market watch: Upcoming market catalysts in Q4 2016.
    Hansen T
    Nat Rev Drug Discov; 2016 Sep; 15(10):671. PubMed ID: 27681788
    [No Abstract]   [Full Text] [Related]  

  • 9. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 10. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market watch: upcoming market catalysts in Q4 2010.
    Rosenthal J
    Nat Rev Drug Discov; 2010 Oct; 9(10):755. PubMed ID: 20885399
    [No Abstract]   [Full Text] [Related]  

  • 14. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
    Lee R
    J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
    [No Abstract]   [Full Text] [Related]  

  • 16. Does $760 m a year of industry funding affect the FDA's drug approval process?
    Wolfe SM
    BMJ; 2014 Aug; 349():g5012. PubMed ID: 25096994
    [No Abstract]   [Full Text] [Related]  

  • 17. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 18. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History, status, and politicization of the FDA.
    Wang W; Wertheimer AI
    Res Social Adm Pharm; 2022 May; 18(5):2811-2816. PubMed ID: 34215537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.